相关实验视频

Updated: Jul 20, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

克罗瓦利马布:在阳性夜间血红素的管理中开启了一个新时代

Aiman Waheed¹, Muhammad Hamza Gul², Abdul Baseer Wardak³

¹Rawalpindi Medical College, Rawalpindi, Pakistan.

Annals of medicine and surgery (2012)

|March 20, 2025

概括

克罗瓦利马布 (Crovalimab) 是一种新的皮下治疗方法,用于治疗阴性夜间血红蛋白尿 (PNH). 这种抗C5抗体通过抑制补充激活,有效地控制PNH,改善患者的治疗结果.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

性夜间血红蛋白尿 (PNH) 是一种罕见的,危及生命的血液疾病,由PIGA基因突变引起,导致补充介导的红细胞破坏.
冠状动脉炎的特征是血液溶解,血栓形成和骨髓衰竭,显著影响患者的发病率和死亡率.
目前的治疗方法旨在抑制补充系统,但为了改善患者管理,需要取得进展.

研究的目的:

评估covalimab的疗效和耐受性,一种新的抗C5循环抗体,用于治疗PNH.
评估covalimab对以前未接受治疗的PNH患者的血红蛋白水平,输血需求和整体患者结局的影响.

主要方法:

这项研究涉及临床试验,包括COMMODORE 3,对PNH患者的covalimab进行评估.
克罗瓦利马布 (Crovalimab) 是一种抗C5抗体,每4周进行一次皮下注射.
治疗的目标是终端补充剂的激活.

主要成果:

克罗瓦利马布在维持PNH患者血红蛋白水平方面表现出有效性.
该药物显著减少了对输血的需求.
在以前没有接受C5抑制剂的患者中观察到高耐受性.

结论:

克罗瓦利马布代表了PNH治疗的重大进步,提供了一个有前途的治疗选择.
它的皮下注射和有效管理补充介导血液溶解使其成为PNH治疗的宝贵补充.
克罗瓦利马布有可能改善PNH和其他补充介导疾病患者的治疗结果.

关键词:

皮加基因 (PIGA) 是一种基因基因.在PNH中,PNH是指PNH.反-c5抗体的抗体.康多尔号试验试验补充介导的破坏是补充介导的破坏.这就是Crovalimab.草甘酸酸氨基醇的使用方法血液溶解 (hemolysis) 是发生在血液中的一个过程.阴性夜间血红素尿症.终端补充激活的激活减少了输血的减少.

更多相关视频

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...